论文部分内容阅读
目的 探讨可溶性细胞间粘附分子 - 1(sICAM - 1)在哮喘发病中的变化及氯雷他定的治疗效应。方法 :采用ELISA法测定经氯雷他定治疗前后的哮喘患儿血清sICAM - 1水平。结果 :哮喘组急性发作期血清sICAM - 1水平明显高于正常对照组 ,经氯雷他定治疗 6～ 8周后血清sICAM - 1水平较治疗前下降 ,但仍高于对照组。结论 :sICAM - 1可作为气道慢性炎症的标记物。氯雷他定具有下调细胞间粘附分子 - 1的作用 ,可用于哮喘的辅助治疗
Objective To investigate the changes of soluble intercellular adhesion molecule - 1 (sICAM - 1) in the pathogenesis of asthma and the therapeutic effect of loratadine. Methods: Serum levels of sICAM - 1 in children with asthma were measured by ELISA before and after treatment with loratadine. Results: Serum levels of sICAM - 1 in asthma group were significantly higher than those in normal control group. Serum sICAM - 1 levels after 6-8 weeks of loratadine treatment were lower than those before treatment, but still higher than those in control group. Conclusion: sICAM - 1 can be used as a marker of chronic airway inflammation. Loratadine has the effect of down-regulating ICAM-1 and can be used in the adjuvant treatment of asthma